Forskning ved Københavns Universitet - Københavns Universitet


Mulighed for aendring af ordinationsmønster

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

In 2005 the Central Drug Committee in co-operation with the hospitals in the county of Copenhagen (H:S) focused on the increasing use of and expenditure derived from three tumour necrosis factor alpha (TNF-alpha) inhibitors. While the three inhibitors are estimated to be equivalent regarding efficacy and safety, eternacept and adalimumab are twice as expensive as infliximab. With a little effort, the Central Drug Committee succeeded in changing clinicians' prescription pattern in a cost-effective manner.
Udgivelsesdato: 2009-Sep
TidsskriftUgeskrift for læger
Udgave nummer37
Sider (fra-til)2655-6
Antal sider2
StatusUdgivet - 2009

ID: 20649539